

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2010

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-50298
(Commission File Number)

98-0376008
(IRS Employer
Identification No.)

Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem, Israel 91390
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: 972-2-566-0001

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 7.01 REGULATION FD DISCLOSURE

On February 10, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing that its Chief Scientific Officer, Miriam Kidron, Ph.D, was chosen to lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February 11, 2010. Dr. Kidron will present the following abstract in Hall B at 3:15 pm: “Assessment of Oral Insulin Formulations in the Healthy Male Volunteers – Safety and Pharmacodynamic Comparisons”.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit Number	Description
-------------------	-------------

99.1	Press Release dated February 10, 2010.
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 11, 2010

ORAMED PHARMACEUTICALS INC.

By: /s/ Nadav Kidron

Nadav Kidron

President, CEO and Director

Exhibit Index

Exhibit Number	Description
99.1	Press Release dated February 10, 2010.



**Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to
Lecture at the Third International Conference on Advanced
Technologies and Treatments for Diabetes in Basel, Switzerland**

JERUSALEM, Israel – February 10, 2010– Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (www.oramed.com), a developer of alternative drug delivery systems, announced today that its Chief Scientific Officer, Miriam Kidron, Ph.D., was chosen to lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February 11, 2010. Dr. Kidron will present the following abstract in Hall B at 3:15 pm: "Assessment of Oral Insulin Formulations in the Healthy Male Volunteers – Safety and Pharmacodynamic Comparisons".

Based on the conference website, the conference "presents professionals with cutting-edge technologies from entrepreneurs racing to develop effective and advanced devices and systems for the treatment and prevention of diabetes and related illnesses." For more information please visit the conference website at: <http://www2.kenes.com/attd/pages/home.aspx>.

Oramed is currently conducting a Phase 2B clinical trial in South Africa on its flagship product an oral insulin capsule. Results are expected at the end of the first quarter of 2010.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oramed, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and Oramed's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to Oramed's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of Oramed to differ materially from those expressed or implied in such forward looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.



Company and Investor Relations Contact:

Oramed Pharmaceuticals Inc.

Tara Horn

USA: +1-646-240-4193

Int'l: + 972-54-334-318

Office: + 972-2-566-0001

Email: tara@oramed.com
